sipatrigine has been researched along with Brain Vascular Disorders in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hobbiger, S; Hussein, Z; Lamb, RJ; Mercer, AJ; Posner, J | 1 |
| George, CF; Hamilton, SJ; Hobbiger, SF; Lees, KR; Lunnon, MW; Muir, KW | 1 |
| Fraser, IJ; Hobbiger, SF; Hussein, Z; Lees, KR; Lunnon, MW; Muir, KW; Posner, J | 1 |
3 trial(s) available for sipatrigine and Brain Vascular Disorders
| Article | Year |
|---|---|
The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers.
Topics: Blood Pressure; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Heart Rate; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neuroprotective Agents; Piperazines; Placebos; Pyrimidines; Reference Values; Respiration | 1995 |
A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke.
Topics: Cerebrovascular Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Infusions, Intravenous; Neuroprotective Agents; Piperazines; Placebos; Pyrimidines | 1995 |
Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions.
Topics: Aged; Cerebrovascular Disorders; Double-Blind Method; Female; Gas Chromatography-Mass Spectrometry; Humans; Infusions, Intravenous; Male; Middle Aged; Neurons; Neuroprotective Agents; Piperazines; Pyrimidines; Sodium Channel Blockers | 1996 |